Gavreto™ (pralsetinib) – New orphan indications
December 1, 2020 - Blueprint Medicines announced the FDA approval of Gavreto (pralsetinib), for the treatment of (1) adult and pediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy and (2) adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Top